Context Partial lipodystrophy (PL) is associated with metabolic co-morbidities but may go undiagnosed as the disease spectrum is not fully described. Objective The objective of the study was to define disease spectrum in PL using genetic, clinical (historical, morphometric) and laboratory characteristics. Design Cross-sectional evaluation. Participants Twenty-three patients (22 with familial, one acquired, 78Á3% female, aged 12-64 years) with PL and nonalcoholic fatty liver disease (NAFLD). Measurements Genetic, clinical and laboratory characteristics, body composition indices, liver fat content by magnetic resonance imaging (MRI), histopathological and immunofluorescence examinations of liver biopsies. Results Seven patients displayed heterozygous pathogenic variants in LMNA. Two related patients had a heterozygous, likely pathogenic novel variant of POLD1 (NM002691Á3: c.3199 G>A; p.E1067K). Most patients had high ratios (>1Á5) of percentage fat trunk to percentage fat legs (FMR) when compared to reference normals. Liver fat quantified using MR Dixon method was high (11Á3 AE 6Á3%) and correlated positively with haemoglobin A1c and triglycerides while leg fat by dual-energy X-ray absorptiometry (DEXA) correlated negatively with triglycerides.
Introduction
Partial lipodystrophy (PL) is a cluster of rare heterogeneous diseases characterized by selective loss of adipose tissue, which places patients at risk of common conditions typically associated with metabolic syndrome. [1] [2] [3] Commonly associated features are insulin resistance and diabetes, hypertriglyceridaemia and nonalcoholic fatty liver disease (NAFLD). 4 PL may be acquired or inherited and pathogenic variants in multiple genes have been identified as causative for inherited PL including LMNA, PPARG, PLIN1, AKT2, CIDEC 2 and more recently LIPE 5 and ADRA2A. 6 One obstacle in development of novel treatment strategies for these disorders has been the lack of documentation of the differentiating features of these syndromes from more common forms of truncal obesity with metabolic syndrome and Type 2 diabetes. This was noted during the Advisory Meeting of the FDA for approval of Metreleptin for the treatment of lipodystrophy syndromes (http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM379648.pdf). Another problem is the lack of objective description of natural history and disease burden. Stated differently, are patients with PL facing different clinical problems, comorbidity risk and mortality compared to patients with more common metabolic disorders such as Type 2 diabetes and truncal obesity? If the answers to these questions are yes, then the pursuit of specific treatments for these disorders will be of high value despite the small number of patients afflicted with PL.
Our study is one of the first in the field to specifically describe the baseline drug-na€ ıve state of patients participating in a drug trial. Accumulation of data such as these presented here may allow more precise definition of the disease state, possibly helping the development of specific diagnostic criteria or disease severity scores. We also hope to increase recognition of similar patients by providing extensive clinical data to endocrinologists.
Methods
We have been recruiting patients with PL for an open-label study conducted at the University of Michigan funded by NIDDK (approved by University of Michigan IRBMED) to evaluate the molecular effects of an investigational drug on treating liver disease associated with PL (ClinicalTrials.gov identifier: NCT01679197, HUM00058708). Here, we describe baseline characteristics of 23 patients who completed screening and study initiation procedures but have not received any investigational drug. Diagnosis of PL was based on physician assessment with evidence of selective loss of body fat. 3 Patients with both inherited and acquired forms of PL were included, excluding lipodystrophy associated with human immunodeficiency virus (HIV). Patients entering this study had a liver ultrasound showing the presence of fatty liver disease or prior biopsy showing evidence of non-alcoholic steatohepatitis (NASH), no evidence of other forms of liver disease and alcohol consumption of <40 g/week. After informed consent was obtained from all patients or guardians, physical examinations were performed and previous medical records were examined to verify historical details. Blood samples after overnight fast were analyzed for estimating leptin levels using a commercial enzyme linked immunosorbent assay (ELISA) kit (EMDMilipore, Billerica, MA,USA). Haemoglobin A1c, fasting lipids and hepatic function tests were determined in the Clinical Pathology Laboratory of University of Michigan using auto-analyzer equipment.
Clinical and research resources were used to determine the molecular basis of disease in patients (described in Appendix S1). Body composition was evaluated using anthropometric measurements, including skin thickness and waist and hip circumferences using standardized techniques. Fat and lean body mass were estimated using dual X-ray absorptiometry (DEXA; GE Lunar Prodigy, model PA +41744, Madison, WI, USA). 7 Ratio of percent fat mass of the trunk to percent fat mass of the legs (FMR) was calculated.
For determination of hepatic fat content, magnetic resonance (MR) imaging using quantitative multi-echo Dixon method and multi-echo MR spectroscopy have been employed (method described in Appendix S1 and Figure S1 ). Transcutaneous liver biopsies were performed and total NASH scores were calculated from histopathological examination using the simplified clinical criteria as presented in Table S1 , which is a modified and clinically applied version of NIH NASH Clinical Network Criteria. 8 NASH score equals the sum of scores for steatosis (range, 0-3), lobular inflammation (range, 0-3), hepatocellular ballooning (range, 0-2) and fibrosis (range, 0-4). NAFLD activity score (NAS) includes these parameters, but without fibrosis. In addition, selective liver biopsy specimens were processed for lamin A/C immunofluorescence staining and then scored in a blinded fashion (methods described under Appendix S1).
Statistical analyses were performed using GRAPHPAD Prism version 6Á05 (LaJolla, CA, USA) and SAS version 9Á2 (Cary, NC, USA). Correlations were investigated by calculating Pearson's correlation coefficient. Two-tailed P-value was calculated, and P < 0Á05 was considered statistically significant. For quantitation of lamin immunofluorescence data, statistical significance was determined via one-way ANOVA followed by Tukey's post-hoc test at a threshold of P < 0Á05.
Results

Patient characteristics and genetic evaluation
Twenty-three patients with PL were enrolled who were 12-64 years old (median age, 43 years): 18 female and five male. The majority, 20 patients were Caucasian, two Hispanic and one African-American. Summary characteristics are shown in Table 1 , and detailed clinical data can be found in Tables S2-S5 . Of known genes, LMNA variants were quite common, identified in seven patients. Of these seven patients, five had a heterozygous pathogenic variant at position 482, the hot spot. Four of these patients harboured R482Q pathogenic variant (two sisters, patients 13 and 20, and two unrelated patients, 17 and 18). One patient (patient 21) harboured the previously reported R482W pathogenic variant and was also diagnosed with muscular dystrophy. 9 Patient 10 also harboured a previously reported R60G pathogenic variant 10 and had a history of dilated non-ischaemic cardiomyopathy requiring heart transplant at age 25. Patient 22 was heterozygous for LMNA R349W and had unique clinical features including loss of fat from the face, hands and feet, a large dorsocervical fat pad, proteinuria, cardiomyopathy (believed to be both primary and ischaemic), infertility, hyperandrogenism and alopecia ( Fig. 1 , Tables S2-S5 ). Another interesting laboratory abnormality in patient 22 is low alkaline phosphatase level, typically associated with progeria. 11, 12 There have been two other published instances of this mutation, one in a male patient with similar fat distribution, but without the exaggerated dorsocervical fat pad, diabetes, or other features described here. 13 In addition, a large kindred with focal segmental glomerulosclerosis and proteinuria in association with PL has been reported.
Two related patients (mother and daughter, 6 and 7) had a variant in Exon 26 of POLD1 (NM002691Á3: c.3199G>A; p.E1067K, Fig. 1 , Figures S2 and S3 and Tables S2-S5) which we classified as a variant of unknown significance, which is most likely pathogenic. Two patients (four and nine) did not harbour mutations in the known 15 LD genes (see Appendix S1) interrogated with whole exome sequencing (WES). WES for the other 11 patients is currently in progress but they did not harbour LMNA p.R482 variants using specific sequencing for this locus as described in Appendix S1.
Body composition
All but one patient had a pattern of fat loss consistent with that seen in familial partial lipodystrophy (FPLD) in which there is fat atrophy of the upper and lower extremities as well as the pelvis, with relative fat sparing or accumulation in the neck, trunk and abdomen. One patient had acquired partial lipodystrophy with fat atrophy in the upper body and preservation of fat in the legs. FMR in this patient was 0Á84, while in the other 22 patients, FMR was higher, 1Á78 AE 0Á53. Using the Third National Health and Nutrition Examination Survey (NHANES III) reference data 15 and the conversion to Lunar equipment previously reported, 16 patients were matched for gender, race and age and the majority had FMR well above 95% confidence interval of reference median values (Fig. 1) . We also compared the FMR obtained from our adult female patients with a group of normal and overweight women with a BMI of 20-30 kg/m 2 as well as a group of female diabetic patients with truncal obesity and fatty liver disease ( Figure S4 ) who were age-matched. A cut-off value of 1Á5 would be well above the normal for adult female populations from NHANESIII as well as our two comparator groups with a sensitivity of 86Á7% and specificity of 96Á8%. There were distinctive patients with substantially higher values, most notably patient 22. Leg fat mass was negatively correlated with log-transformed triglycerides (P = 0Á0498, Fig. 2 ). No correlation was found between leg fat mass and haemoglobin A1c (R 2 = 0Á06, Fig. 2 ), or between leg fat mass and liver fat (R 2 = 0Á01). Mid-thigh skin fold thickness (mean: 12Á1 AE 7Á7; range, 4-29 mm) was low compared to age-, gender-and race-matched data from NHANES data 17 (mean: 26Á3 AE 7Á2; range, 12Á3-32Á4 mm).
Leptin levels (mean: 22Á3 AE 16Á6, range 4Á8-67Á1 ng/ml) were variable and in general higher than noted in studies that enrolled only patients with leptin deficiency at the NIDDK, 18 but similar to one of our previously published series. 19 Leptin levels correlated with total fat mass (P = 0Á0071) and trunk fat (P = 0Á0044; Figure S5 ) and did not correlate with HbA1c (R 2 = 0Á00) or triglyceride levels (R 2 = 0Á08).
Comorbidities
Prevalence of comorbidities and medications used are shown in Fig. 3 . All patients had either diabetes (82Á6%) or pre-diabetes (17Á4%) with variable degree of control. Mean AE SD haemoglobin A1c was 8Á6 AE 1Á9%. One patient (patient 14) had Type 1 diabetes with undetectable C-peptide and another patient (patient 15) had positive anti-GAD antibody at baseline. Nearly half (11 patients) had very poor control with haemoglobin A1c above 9%. Nineteen patients (82Á6%) used a glucose lowering agent. Ten patients (43Á5%) used combination therapy with two or more agents. Insulin was used by 12 patients (52Á2%) and 9 of these patients required over 100 units/day. Six patients (26Á1%) used highly concentrated U-500 insulin. Microvascular complications of diabetes were common. Twelve patients (52Á2%) had peripheral neuropathy. One patient had a history of chronic inflammatory demyelinating polyneuropathy (CIDP). Six patients had known diabetic retinopathy based on patient report, although the prevalence may be higher as we did not have dilated examination results for all patients. Proteinuria or microalbuminuria was known in 10 patients (43Á5%). Two patients had kidney biopsies for clinical reasons, one displaying membranoproliferative glomerulonephritis (patient 6, biopsied for massive proteinuria) and another (patient 22, biopsied for haematuria) displaying thin basement membrane disease. One patient had severe gastroparesis.
Twenty-two of 23 patients had hypertriglyceridaemia (mean, 1058 AE 1745 mg/dl). Six had very high triglycerides over 1000 mg/dl. Most (17 patients) used a lipid lowering agent (Fig. 3) . Recurrent pancreatitis occurred in seven of 23 patients 12Á1 (7Á7) %Fat trunk / %Fat legs*, mean (SD) 1Á78 (0Á53) MR spectroscopy liver fat (%), mean (SD)
13Á8 ( (30Á4%). At least three episodes of pancreatitis occurred while triglyceride levels were <800 mg/dl. Two patients who are sisters, with known LMNA gene mutations, were found to have pancreatic cystic lesions on magnetic resonance imaging (MRI). One had a single 0Á3-cm cystic lesion in the pancreatic neck and the other patient had multiple subcentimeter cystic lesions which may represent side branch intraductal mucinous neoplasms ( Figure S6 ). Mood disorder requiring medication was identified in 12 patients (52Á2%). Depression was the most common psychiatric condition, present in 10 patients (43Á5%). Six had anxiety (26Á1%), one patient had bipolar disorder, and one had an unidentified psychiatric condition for which he previously used an antipsychotic agent.
Chronic pain was common among our patients. Eighteen patients (78Á3%) reported some type of painful condition including neuropathy (52Á2%), arthritis (47Á8%), chronic back pain (13Á0%), fibromyalgia (17Á4%) and myopathy (39Á1% had either suspected or confirmed myopathy). One patient had muscular dystrophy.
Other noted conditions include coronary artery disease or myocardial infarction in five patients (22Á7%), one patient with ischaemic cardiomyopathy and one patient with LMNA mutation and non-ischaemic cardiomyopathy who required a heart transplant. Hypertension was present in 13 patients (56Á6%). Seven patients (30Á4%) had sleep apnoea. Three (13%) had asthma or emphysema. Nine patients (39Á1%) had polycystic ovarian syndrome (PCOS).
Hepatic evaluation
Liver fat quantified using MR spectroscopy and also using MR Dixon method showed fat percentage, mean AE SD of 13Á8 AE 6Á1% and 11Á9 AE 6Á3%, respectively (normal <5%).
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Liver fat was correlated with metabolic parameters. A positive correlation was found between liver fat quantified using MR Dixon method and haemoglobin A1c (P = 0Á0431) as well as log-transformed triglycerides (P = 0Á0096) Fig. 2 .
Of the 23 patients who underwent liver biopsy, 22 met histopathological criteria for NASH. Total NASH scores of those 22 patients ranged 3-9 (mean, 6 AE 2). NAS in patients who met criteria for NASH ranged 3-8 (mean, 5 AE 1). Eighteen patients (78Á3%) had some degree of fibrosis present with variable severity (stage 1a-4). One 12-year-old female patient (patient 15) had stage 4 fibrosis (Fig. 4) .
As LMNA mutations were common among the FPLD patients, and mice with hepatocyte-specific LMNA deletion develop spontaneous steatosis with nuclear alterations and susceptibility to diet-induced steatohepatitis ('unpublished data'; authors: Raymond Kwan, Graham Brady, Maria Brzozowski, Sujith Weerasinghe, Hope Martin, Min-Jung Park, Ram Menon, Xin Tong, Lei Yin, Colin Stewart, M. Bishr Omary), we investigated nuclear envelope integrity from our liver biopsy samples. These early studies were carried out on three patients with LMNA pathogenic variants and one patient with a POLD1 p.E1067K variant. Specimens from two patients with NASH (without lipodystrophy) were used as controls. Immunofluorescence staining of frozen liver sections showed dysmorphic nuclei and lamin disorganization in the patients with LMNA pathogenic variants compared with NASH controls (Fig. 5) . We also observed abnormal nuclear morphology in the patient with POLD1 variant, although not to the same extent as the patients with LMNA variants.
Discussion
The goal of our study is to provide a complete description of the disease state in a cohort of 23 patients with PL. Lack of clear documentation of clinical manifestations and full appreciation of disease burden have become an obstacle in therapeutic development for rare metabolic diseases given the significant heterogeneity in presentation. 21 With this report, we are reintroducing the idea of careful morphometric description using DEXA to document the presence of PL. This approach may be adopted widely as a clinical test following further validation. Also, we are reporting a number of important clinical lessons such as the presence of severe disease burden not only because of metabolic disease but also because of neuropsychiatric symptoms, chronic pain and multi-system involvement. It would be useful to collect similar data from a larger number of patients to develop disease severity scores taking into account the entire spectrum of clinical findings. Our genetic investigations have recapitulated the genetic heterogeneity of PL with multiple patients having different molecular basis for their disease. Several genes have been implicated in various forms of FPLD including LMNA, PPARG, PLIN1, AKT2 CIDEC, LIPE and ADR2A. 2, 5, 6, 22, 23 However, the molecular cause of disease remains unexplained in up to 40% of patients. Lotta et al. recently reported enrichment of multiple common variant genes in a cohort of patients formerly classified as FLPD1, suggesting the possibility of polygenic inheritance.
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LMNA pathogenic variants are most commonly identified in FPLD and also the most common in our cohort. 22 As novel findings, we have described two unique phenotypes, one of which is associated with an uncommon LMNA variant (R349W), characterized by specific body composition and clinical features. We are able to add previously unrecognized clinical characteristics (dorsocervical fat pad, ischaemic cardiac disease and low alkaline phosphatase) to the description of this genotype. 13 As another novel finding, two related patients (mother-daughter) were found to have a heterozygous variant of uncertain significance in POLD1 that is possibly pathogenic and associated with dysmorphic nuclei in the liver. POLD1 has been previously implicated in lipodystrophy syndromes. An in-frame deletion mutation in POLD1 was discovered in two patients with mandibular hypoplasia, deafness and progeroid features (MDP) syndrome with lipodystrophy. 25 Our patients did not have clinical evidence for deafness or progeroid features, but had small mandibles and fluctuating creatine kinase (CK) levels. Our findings need to be complemented with further functional characterization of the observed variant. However, glutamine in position 1067 is highly conserved, within the second zinc module of the zinc finger domain and projected to be pathogenic using in silico algorithms ( Figure S3 ). Another area of interest for us was to determine whether unique morphometric characteristics could be objectively used as diagnostic criteria. Previously, the use of mid-thigh skin thickness has been suggested as a field tool to screen FPLD, 3, 26 and this criterion has been adopted into the consensus statement developed by AACE 3 as well as the most recent multisociety effort. 27 In fact, recently, Guillin-Amarelle et al. have described skin-fold characteristics of patients with the Koberling varierty of PL, attributing a Koberling Index, the ratio of subscapular to calf skinfolds (K€ oB index), with a cut-off value of 3Á477 to be good predictor of this subtype of PL (sensitivity, 89%; specificity, 84%). 28 However, accurate measurement of skin thickness may be tricky in some patients in our experience and we have observed high inter-observer variability while collecting data. Body composition in our patients as analyzed using DEXA showed a high FMR when compared to normative data obtained from NHANES reference data, 15 highlighting the loss of fat in extremities seen in all of our patients who were classified as having FPLD. Others have proposed this approach previously in both female patients harbouring LMNA pathogenic variants and in patients with HIV-associated lipodystrophy. 26, 29 In our hands, an FMR above 1Á5 (obtained using GE Lunar DEXA systems) in adult females may indicate an abnormal ratio compared to a reference population taking multi-ethnic or agerelated variation into account. We are not able to suggest a cutoff value for male patients or children in our cohort. Further analysis of fat-related parameters in larger groups of lipodystrophy patients and comparison to patients with common metabolic syndrome, and abdominal obesity may help establish objective diagnostic criteria for PL. We also present novel data showing that low leg fat was correlated with higher triglycerides in our unique population, suggesting a pathogenic link between higher triglycerides and low leg fat. Other researchers have reported a similar association from other cohorts, and our patients possibly display the most variants. For each group, 3-4 randomly selected high-power fields were scored for each patient liver section (>150 nuclei per field, >700 nuclei per patient). Statistical significance was determined by one-way ANOVA followed by Tukey's post hoc test at a threshold of P < 0Á05. Error bars represent the standard error of the mean.
extreme version of this association. 30, 31 Further strengthening a pathogenic role for absence of femoral fat, Van Pelt and colleagues have observed worsening lipemia after femoral lipectomy. 32 In contrast, higher fat in the liver in our patients is associated with worse glucose control and higher triglycerides (shown for the first time in a PL cohort), similar to studies in patients with Type 2 diabetes. 33 These findings suggest that the development of hypertriglyceridaemia may be related to absence of peripheral fat depots (and possibly related to changes in their adipokines), but also because of accumulation of ectopic fat, allowing both mechanisms to be exploited for therapeutic development.
As expected in patients with lipodystrophy, our patients had a high prevalence of diabetes, often associated with extreme insulin resistance. The incidence of diabetes was higher in our population (82Á6%), compared with that of a previously reported cohort (50%). 34 This discrepancy may be because of recruitment of patients suspected to have NAFLD, and these patients may have more severe metabolic co-morbidities. Microvascular complications of diabetes, particularly peripheral neuropathy and nephropathy were also common. Hypertriglyceridaemia and NAFLD or NASH are known to have associations with lipodystrophy, and most of our patients also demonstrated this. 2 Other frequent conditions included recurrent pancreatitis, hypertension, PCOS, gastroesophagal reflux disease (GERD), sleep apnoea and coronary artery disease or myocardial infarction. Diabetes commonly co-exists with hypertension, hyperlipidaemia, kidney disease and cardiovascular disease. 35 However, we were surprised by the prevalence of chronic pain and mood disorder in this group. Overall, chronic pain was present in 78Á3% of patients and was reported to be because of a combination of arthritis, back pain, fibromyalgia and myopathy. Depression has been shown to be prevalent in adults with diabetes to a varying degree (11-32%), 36 but appears higher in our patients (43Á5%). It is not clear whether these under-appreciated manifestations are because of primary pathophysiological pathways, a manifestation of ectopic lipid (or other metabolite) deposition in muscles and nerves (or elsewhere) or because of some other adaptive (neurobehavioural, possibly functional) processes. We further explored the extent of liver disease and NASH by histopathological criteria was present in nearly all patients (22 of 23). As our trial specifically sought patients with fatty liver disease at baseline, the presence of NASH may be overrepresentative of the prevalence of NASH in the entire population of PL. It is noteworthy that significant fibrosis may be present even in young patients without diabetes as was shown in a 12-year-old female patient. Therefore, it would be important to consider a liver biopsy or a careful investigation for clinical fibrosis even in very young patients with PL.
Lastly, we present data that reflect relative nuclear integrity in the liver tissue of PL. Lamin A and lamin C are integral components of the nuclear envelope and are expressed ubiquitously throughout the body. Alterations in the nuclear envelope may lead to premature cell apoptosis. LMNA pathogenic variants may increase the risk of arrhythmia or cardiomyopathy, as occurred in two of our patients with non-ischaemic cardiomyopathy (one requiring cardiac transplantation). 37 Given that patients had multi-system involvement, we examined the degree of nuclear disorganization in liver biopsy tissues of select patients. Patients with LMNA pathogenic variants had apparent nuclear disorganization in their liver tissue. We also noted a similar pattern, although not to the same degree, in a patient harbouring a POLD1 variant of uncertain significance that is likely pathogenic. We posit nuclear atypia and disorganization may be a unifying cellular phenomenon in patients with PL depending on the mutation and the involved gene. This phenomenon may contribute to the multisystem involvement in PL.
Further work is warranted in this arena. Overall, PL was associated with involvement of at least 10 organ systems (with manifestations present in all 10 in nearly 40% of patients). The involvement of multiple organs in PL bears some resemblance to other heterogeneous rare metabolic diseases such as glycogen storage disease. Researchers studying Gaucher disease have developed a disease severity score tool, 38 making use of the number of organ systems affected, severity of signs and symptoms and functional limitations. The diversity of comorbid conditions in our patients has inspired us to propose adoption of a similar approach to define the disease burden more objectively. If such a tool can be developed and validated, the impact of disease modifying treatments can be better measured.
